Urinary Tract Infection Market to grow at a CAGR of 2.0% during 2025 to 2035; Driven by Rising Prevalence of Urinary Tract Infections and Increasing Antibiotic Resistance Concerns

Urinary Tract Infections Market Report Highlights

The Global Urinary Tract Infection Market size was valued at USD 10.8 Billion in 2024, and the market is projected to grow from USD 11.02 Billion in 2025 to USD 13.43 Billion by 2035, registering a CAGR of 2.0% during the forecast period 2025–2035.

A urinary tract infection (UTI) is an infection in any part of the urinary system such as kidneys, ureters, bladder, and urethra. UTIs can be caused for a variety of causes, including unsafe sex, lack of hygiene, and diabetes. UTIs are more common in women than men due to inherent complications in the female reproductive system. According to the World Health Organization, 1 million hospitalizations of women occur each year due to UTIs, which affects almost half of the female population around the world.

The growth of the global urinary tract infections market is attributed to the increasing prevalence of diabetes and kidney stones. The launch of combination drugs is also resulting in market growth. The rise in research & development (R&D) of a novel class of antibiotics for UTIs is also expected to aid in the growth of the market.

For instance, in August 2020, researchers at the California Polytechnic State University reported the development of a new class of antibiotics for UTIs, which targets bacterial iron uptake, at the American Chemical Society (ACS) Fall 2020 Virtual Meeting & Expo. Moreover, in July 2019, The US Food and Drug Administration has approved Merck & Co., Inc.’s Recarbrio (imipenem, cilastatin, and relebactam), an antibacterial drug to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Segment Analysis

Global Urinary Tract Infections Market has been divided based on drug class, application, pathogen, and end user. The market, based on drug class, has been segmented into quinolones, β-lactam & cephalosporins, aminoglycosides, penicillin, and azoles. The quinolones are further sub-segmented into ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, and fleroxacin. The cephalosporin is divided into avycaz, cedax, cefdinir, and cefditoren. β-lactam is further segmented into amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime-proxetil.

The market, based on application, has been bifurcated into urethritis, cystitis, and pyelonephritis. The market, based on pathogen, has been bifurcated into Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis. On the basis of end-user, the global urinary tract infections market has been classified as hospitals, clinics, self-administered, and others.

Regional Analysis

The global UTI market, on the basis of region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. In 2019, the Americas accounted for the largest share of the global market. This large share is majorly attributed to the presence of key manufacturers, the rising prevalence of UTIs, and the growing aging woman population in the region. Europe is the second-largest regional market in terms of revenue.

Urinary disorders account for a tremendous economic burden in Europe. The high-income countries, the EU5 (France, Germany, Italy, Spain, and the UK), typically spend 2–3% of their annual health budget on the treatment of urinary disease as per a bulletin published by the WHO.

Asia-Pacific is expected to be the fastest-growing market for UTI during the forecast period. This can be attributed to the developing economies and highly populated countries such as China, India, and South Korea. The African market is growing and will continue to grow at a steady pace. The rapid urbanization in these countries has led to increased exposure to numerous environmental toxins, a highly infectious disease burden, and rising incidences of non-communicable diseases.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Urinary Tract Infections Market— Pfizer Inc, Novo Nordisk A/S, Novartis Ag, Merck & Co., Inc, Eli Lily and Company, Allergan, Cipla Inc, Teva Pharmaceuticals, GlaxoSmithKline Plc, and Bayer AG.

Key Findings of the Study

• Technological advancements in diagnostics are enhancing the accuracy and speed of urinary tract infection detection in North America.


• The Asia-Pacific region is emerging as the fastest-growing market, driven by rising healthcare access and awareness.


• Quinolones remain the largest segment in terms of treatment options, while beta and cephalosporins are witnessing rapid growth.


• The rising incidence of urinary tract infections and the growth of the elderly population are key drivers propelling market expansion.